Representation

As FDA counsel, negotiated guilty plea and at the time the largest fine of a generic drug manufacturer
for cGMP violations. Assisted in overturning negative FDA advisory panel eventually securing FDA NDA
approval. Secured FDA reversal of combination drug/device designation. Negotiated waiver
of new drug exclusivity with competitor company resulting in $10m payment.